Research & Development
Professional, Innovation, and Respect of life
We are a global, new drug developing biopharmaceutical company provide only evidence-based medicine.
Established in 2008, SynCore was cofounded by Sinphar Group and National Health Research Institute (NHRI) Taiwan. We focus on creating values of new drug by R&D management and integration of technology resources. SynCore’s pipeline concentrates on oncology, ophthalmology, and dermatology fields, continuously dedicates in helping patients worldwide.
SynCore Biotechnology Announces Interim Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1)
SynCore Biotechnology (4192:TT) receives interim analysis results for its global phase [...]
SynCore’s global phase III clinical trial on pancreatic cancer second-line therapy, [...]
Syncore Biotechnology will attend the Biotech Showcase 2022 Conference virtually on [...]
SynCore Biotechnology (SynCore Bio) is pleased to announce that it will [...]